| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 07/01/2004 | US20040127699 Cosmetics, drugs |
| 07/01/2004 | US20040127554 Dermatological and cosmetic compositions |
| 07/01/2004 | US20040127544 Mannich base prodrugs of 3-(Pyrrol-2-yl-methylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127542 1-(Pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127537 Stable liquid parenteral parecoxib formulation |
| 07/01/2004 | US20040127532 Method for synthesizing leflunomide |
| 07/01/2004 | US20040127528 Metalloproteinase inhibitors |
| 07/01/2004 | US20040127508 Substituted pyrazolopyrimidines and thiazolopyrimidines |
| 07/01/2004 | US20040127492 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
| 07/01/2004 | US20040127485 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists |
| 07/01/2004 | US20040127474 Contacting the cell with a ptc agonist in a sufficient amount to inhibit the altered growth state, wherein the ptc agonist is a organic molecule having a molecular weight less than about 750 amu for inhibiting an altered growth state of a cell |
| 07/01/2004 | US20040127452 C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them |
| 07/01/2004 | US20040127438 polypeptide (or its encoding nucleic acid molecule from Mycobacterium tuberculosis or related prokaryotes in the treatment of cancer, allergic disorders or conditions of immunoactivation, particularly asthma |
| 07/01/2004 | US20040127426 Peptidic compounds as cysteine protease inhibitors |
| 07/01/2004 | US20040127420 Metalloproteinase inhibitors for wound healing |
| 07/01/2004 | US20040127408 based on the complementarity-determining region (CDR) of a human monoclonal anti-DNA antibody |
| 07/01/2004 | US20040127389 Effervescent solid composition of matter |
| 07/01/2004 | US20040126878 Method for the preparation of immunologically inert amniotic membranes |
| 07/01/2004 | US20040126825 Using a compounds ability to decrease integrin activation as a diagnostic tool for the identification of antagonistic modulators of neovascularizaton; antitumor/antiproliferative agents |
| 07/01/2004 | US20040126799 First nucleotide sequence comprises adenine residue at position 1033 or equivalent; reducing disease treatment side effects |
| 07/01/2004 | US20040126759 Molecules for disease detection and treatment |
| 07/01/2004 | US20040126758 homologous to the known fibrinogen derived haptotactic peptides; shown to elicit activity from fibroblasts, endothelial and smooth muscle cells; for wound healing and enhancing osteogenesis/angiogenesis in vivo with/without medical implant |
| 07/01/2004 | US20040126353 using serine protease inhibitors and botanical extracts of the legume family to delay hair growth, reduce hair follicle and hair shaft size and hair shaft pigmentation, |
| 07/01/2004 | CA2509611A1 Method of treatment for sexual dysfunction |
| 07/01/2004 | CA2509600A1 Pharmaceutical uses for alpha2delta ligands |
| 07/01/2004 | CA2508045A1 Novel compounds having selective inhibiting efect at gsk3 |
| 07/01/2004 | CA2505406A1 Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate |
| 06/30/2004 | EP1433783A2 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 06/30/2004 | EP1433780A1 19-nor-vitamin D3 compounds with calcemic activity |
| 06/30/2004 | EP1433484A1 Use of interleukin-18 for treating skin disorders associated with UV radiation |
| 06/30/2004 | EP1433481A1 The use of methyltestosterone for the treatment of human papilloma virus infections |
| 06/30/2004 | EP1432991A1 Identification and isolation of somatic stem cells and uses thereof |
| 06/30/2004 | EP1432801A2 Receptors and membrane-associated proteins |
| 06/30/2004 | EP1432735A2 Antagonistic anti-htnfsf13b human antibodies |
| 06/30/2004 | EP1432734A1 Cytokine receptor |
| 06/30/2004 | EP1432724A1 Rna interference mediated inhibition of map kinase genes |
| 06/30/2004 | EP1432723A2 Modulation of the expression of genes dependent on stat-1 |
| 06/30/2004 | EP1432703A1 Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| 06/30/2004 | EP1432700A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 06/30/2004 | EP1432454A2 Methods for sterilizing preparations containing albumin |
| 06/30/2004 | EP1432452A2 Inhibition of stat-1 |
| 06/30/2004 | EP1432435A1 Enamel matrix protein compositions for modulating immune response |
| 06/30/2004 | EP1432431A2 Methods and compositions for modulating interleukin-21 receptor activity |
| 06/30/2004 | EP1432427A1 Composition of hypochlorous acid and its applications |
| 06/30/2004 | EP1432426A2 USE OF UNMETHYLATED CpG |
| 06/30/2004 | EP1432414A1 Use of tazarotene for preparing a nail varnish for treating and/or preventing psoriasis and nail varnish containing same |
| 06/30/2004 | EP1432413A2 3,4-methylenedioxy-substituted chalcones as therapeutic agents |
| 06/30/2004 | EP1432408A1 Pharmaceutical compositions comprising colloidal silicon dioxide |
| 06/30/2004 | EP1432399A1 Enhancing epidermal barrier development in skin |
| 06/30/2004 | EP1315730B1 1-(alkyl), 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo(1,2-a)pyrimidin-5(1h)-one derivatives |
| 06/30/2004 | EP1264548A4 Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy |
| 06/30/2004 | EP1244418B1 Oil-in-water type cosmetic or dermatological preparations |
| 06/30/2004 | EP1173413B1 Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors |
| 06/30/2004 | EP1149072B1 Sulfonamide hydroxamates |
| 06/30/2004 | EP1037880B1 Retinoic acid mimetic anilides |
| 06/30/2004 | EP1009421B1 Compositions for enhanced wound healing |
| 06/30/2004 | EP0971908B1 Il-8 receptor antagonists |
| 06/30/2004 | CN1509337A New polynucleotides and polypeptides of IFN alpha-17 gene |
| 06/30/2004 | CN1509328A Use of opg ligand to modulate immune response |
| 06/30/2004 | CN1509291A Oxazolo-and-furopyrimidines and their use in medicaments against tumors |
| 06/30/2004 | CN1509288A The citrate salt of 5,8,14-triazatetracyclo (10.3.1.0.2,11.0.4,9)-hexadeca-2.(11),3,5,7,9-pentaene |
| 06/30/2004 | CN1509286A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509283A Novel pyridyl cyanoguandine compounds |
| 06/30/2004 | CN1509280A 手性化合物 Chiral compounds |
| 06/30/2004 | CN1509276A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509275A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509274A Metallo proteinase inhibitors |
| 06/30/2004 | CN1509273A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509272A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509267A Thyroid hormone receptor atagonists for treating cardiac and metabolic disorders II |
| 06/30/2004 | CN1509184A Antipruritscs |
| 06/30/2004 | CN1509179A External skin composition |
| 06/30/2004 | CN1509174A Tartrate salt of 5,8,14-triazatetracyclo [10,3,1,02,11.04,9]-hexzdeca-2(11),3,5,7,9-pentaene |
| 06/30/2004 | CN1509162A Cosmetics |
| 06/30/2004 | CN1508154A Method for preparing injection collagen, and product and use thereof |
| 06/30/2004 | CN1507924A Preparation method for producing fibrin gel and platelect gel using human thromblase |
| 06/30/2004 | CN1507913A Medicinal composition for treating wound surface |
| 06/30/2004 | CN1507888A Four-ingredient two dosage-form burn-empyrosis medicine and preparing process thereof |
| 06/30/2004 | CN1507887A Chinese medicine for treating facial skin disease |
| 06/30/2004 | CN1507860A Complex prescription preparation of local application for promoting chronic wound healing |
| 06/30/2004 | CN1507851A Cosmetic containing purple bergenia herb element and method for extracting said element |
| 06/30/2004 | CN1155648C Silicone gel containing salicylic acid |
| 06/30/2004 | CN1155600C 2,3-diaryl-pyrazolo[1,5-B] pyridazines derivatives, their prepn. and use as cyclooxygenase 2(cox-2) inhibitors |
| 06/30/2004 | CN1155569C Indolin derivs. as sun protection agents |
| 06/30/2004 | CN1155405C Recipe and prepn. of medicine for treating diabetic ulcer and preparation method |
| 06/30/2004 | CN1155386C Nailpolish having function of resisting psoriasis |
| 06/30/2004 | CN1155376C 9-cis-retinonic acid and medicinal use of salt and ester thereof |
| 06/30/2004 | CN1155359C Compositions contg. antifungal and phospholipid |
| 06/29/2004 | US6756481 IL-23 receptor binding compositions |
| 06/29/2004 | US6756480 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| 06/29/2004 | US6756382 Amide substituted imidazoquinolines |
| 06/29/2004 | US6756381 A purified antitumor agent is crystallized from acetone or dichloromethane |
| 06/29/2004 | US6756380 5-phenyl-pyrimidine derivatives |
| 06/29/2004 | US6756376 Preventing fatty acid release |
| 06/29/2004 | US6756371 Morpholino or thiomorpholino derivatives; respiratory system disorders |
| 06/29/2004 | US6756362 Anionic polymers including dermatan sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, heparin, dextran sulfate, pentosan polysulfate, hyaluronic acid and alginate. |
| 06/29/2004 | US6756047 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs |
| 06/29/2004 | US6756045 Topically applied idebenone-containing agent with protective and regenerative effect |
| 06/29/2004 | CA2105215C Novel oxazolidines |
| 06/29/2004 | CA2031518C Endothelial cell-leukocyte adhesion molecules (elams) and molecules involved in leukocyte adhesion (milas) |